GlassScriptPhysician profile
Amardeep Sodhi
NPI 1366406464
$10,235.70
in general payments reported to CMS, 2019-2025
24 companies · $925 in 2025
The $925 reported for 2025 was more than what 77% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $845 · 2020: $2,637 · 2021: $1,002 · 2022: $1,376 · 2023: $1,316 · 2024: $2,134 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,365 · Education: $10.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,365.10 |
| Education | $10.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $2,964.28 | 2019-2025 | Arikayce, Brinsupri |
| Viiv Healthcare Company | $1,716.70 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $1,523.97 | 2019-2025 | Veklury |
| Merck Sharp & Dohme LLC | $1,106.07 | 2019-2025 | Pifeltro, Zerbaxa, Dificid |
| Abbvie INC. | $425.58 | 2021-2025 | Dalvance |
| Astellas Pharma US INC | $396.02 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $366.37 | 2021-2024 | Nuzyra |
| Melinta Therapeutics, LLC | $346.53 | 2019-2024 | Rezzayo, Kimyrsa, Orbactiv |
| Shionogi INC | $314.84 | 2022-2025 | Fetroja |
| Janssen Products, LP | $184.95 | 2022 | |
| Theratechnologies INC. | $165.63 | 2019-2025 | Egrifta, Trogarzo |
| Mayne Pharma Commercial LLC | $137.89 | 2019-2021 | |
| Napo Pharmaceuticals INC | $128.43 | 2023-2025 | Mytesi |
| Depuy Synthes Sales INC. | $112.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.49 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $85.29 | 2023-2025 | Airsupra, Breztri |
| Allergan, INC. | $46.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| La Jolla Pharmaceutical Company | $20.55 | 2024 | Xacduro |
| Daiichi Sankyo INC. | $20.28 | 2020 | |
| Aimmune Therapeutics, INC. | $18.82 | 2024 | |
| Lilly USA, LLC | $13.69 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.19 | 2019 | |
| Advanced Oxygen Therapy INC. | $11.60 | 2025 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amardeep Sodhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.